



HUTCHISON CHINA MEDITECH LIMITED

**Hutchison China MediTech Limited (“Chi-Med”)
(AIM: HCM)**

Results of Annual General Meeting

London: Friday, 24 April 2015: Chi-Med today announces that all ordinary resolutions and special resolution put to its Annual General Meeting (“AGM”) held on 24 April 2015 were duly passed. The poll results of the resolutions were as follows:

Resolutions	Number of Votes (%)*		
	For	Against	Withheld [#]
1 To consider and adopt the statement of audited accounts and the reports of the directors and independent auditor for the year ended 31 December 2014.	45,726,732 (99.9344%)	30,030 (0.0656%)	0
2 (a) To re-elect Mr Shigeru Endo as a director.	45,670,732 (99.8120%)	86,030 (0.1880%)	0
(b) To re-elect Mr Christian Salbaing as a director.	45,670,732 (99.8120%)	86,030 (0.1880%)	0
(c) To re-elect Ms Edith Shih as a director.	45,670,732 (99.8120%)	86,030 (0.1880%)	0
(d) To re-elect Mr Christopher Nash as a director.	45,756,762 (100%)	0 (0%)	0
(e) To re-elect Mr Michael Howell as a director.	45,756,762 (100%)	0 (0%)	0
(f) To re-elect Professor Christopher Huang as a director.	45,756,762 (100%)	0 (0%)	0
3 To re-appoint PricewaterhouseCoopers as the auditor of Chi-Med and authorise the board of directors to fix the auditor’s remuneration.	45,756,762 (100%)	0 (0%)	0
4 Ordinary Resolution No. 4(A) : To grant a general mandate to the directors of Chi-Med to issue additional shares.	45,756,762 (100%)	0 (0%)	0
Special Resolution No. 4(B) : To disapply pre-emption rights.	43,526,062 (95.1249%)	2,230,700 (4.8751%)	0
Ordinary Resolution No. 4(C) : To grant a general mandate to the directors of Chi-Med to repurchase shares of Chi-Med.	45,755,162 (99.9965%)	1,600 (0.0035%)	0
5 Ordinary Resolution : To adopt the new share option scheme of Chi-Med.	40,873,095 (92.2752%)	3,421,667 (7.7248%)	1,462,000
6 Ordinary Resolution : To adopt the long term incentive plan of Chi-Med.	41,434,230 (93.5421%)	2,860,532 (6.4579%)	1,462,000

* Percentages rounded to 4 decimal places

[#] A vote withheld is not a vote in law and is not counted in the calculation of the proportion of the votes for and against a resolution.

As at the date of the AGM, the number of issued shares of Chi-Med was 53,299,964, which was the total number of shares entitling the holders to attend and vote on the ordinary resolutions and special resolution proposed at the AGM.

Ends

Enquiries

Chi-Med

Christian Hogg, CEO

Telephone: +852 2121 8200

Panmure Gordon (UK) Limited

Richard Gray

Andrew Potts

Telephone: +44 20 7886 2500

Citigate Dewe Rogerson

Anthony Carlisle

David Dible

Telephone: +44 20 7638 9571

Mobile: +44 7973 611 888

Mobile: +44 7967 566 919

About Chi-Med

Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases. Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China. Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

Chi-Med is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13). For more information, please visit: www.chi-med.com.